CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX

CenterBook Partners LP acquired a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 159,421 shares of the company’s stock, valued at approximately $1,880,000. CenterBook Partners LP owned 0.21% of Definium Therapeutics at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP grew its stake in shares of Definium Therapeutics by 31.9% in the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after purchasing an additional 828,067 shares in the last quarter. Commodore Capital LP grew its position in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after buying an additional 475,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after buying an additional 198,878 shares during the period. Diadema Partners LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $1,029,000. Finally, Stempoint Capital LP acquired a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $590,000. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Trading Down 0.6%

Shares of DFTX opened at $17.27 on Friday. The business’s 50-day moving average price is $15.07 and its 200 day moving average price is $12.49. The stock has a market capitalization of $1.70 billion, a P/E ratio of -8.47 and a beta of 2.57. Definium Therapeutics, Inc. has a 1-year low of $4.70 and a 1-year high of $18.70. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Jefferies Financial Group initiated coverage on Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Finally, JonesTrading initiated coverage on Definium Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and a consensus target price of $35.22.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. The trade was a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of the stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the sale, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. The trade was a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is owned by corporate insiders.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.